Quadrant Capital Group LLC lowered its position in GSK plc (NYSE:GSK – Free Report) by 5.3% in the second quarter, HoldingsChannel reports. The fund owned 13,930 shares of the pharmaceutical company’s stock after selling 773 shares during the quarter. Quadrant Capital Group LLC’s holdings in GSK were worth $497,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Centerpoint Advisors LLC raised its position in shares of GSK by 115.8% in the first quarter. Centerpoint Advisors LLC now owns 846 shares of the pharmaceutical company’s stock worth $30,000 after acquiring an additional 454 shares during the period. GW&K Investment Management LLC raised its position in shares of GSK by 215.3% in the first quarter. GW&K Investment Management LLC now owns 1,110 shares of the pharmaceutical company’s stock worth $39,000 after acquiring an additional 758 shares during the period. SRS Capital Advisors Inc. raised its position in shares of GSK by 52.9% in the first quarter. SRS Capital Advisors Inc. now owns 1,090 shares of the pharmaceutical company’s stock worth $39,000 after acquiring an additional 377 shares during the period. WealthPlan Investment Management LLC acquired a new position in shares of GSK in the first quarter worth about $42,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in shares of GSK by 61.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock worth $42,000 after acquiring an additional 368 shares during the period. Institutional investors and hedge funds own 13.53% of the company’s stock.
Analyst Upgrades and Downgrades
Separately, StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, November 1st. Three research analysts have rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $1,553.75.
GSK Stock Up 2.2 %
Shares of NYSE GSK opened at $35.20 on Friday. GSK plc has a 12-month low of $32.69 and a 12-month high of $39.74. The stock has a market cap of $72.07 billion, a PE ratio of 9.46, a P/E/G ratio of 1.65 and a beta of 0.66. The company has a current ratio of 0.95, a quick ratio of 0.70 and a debt-to-equity ratio of 1.27. The company has a 50-day moving average of $36.08 and a 200 day moving average of $35.47.
GSK Cuts Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 17th will be paid a dividend of $0.3398 per share. The ex-dividend date is Thursday, November 16th. This represents a $1.36 annualized dividend and a yield of 3.86%. GSK’s dividend payout ratio is presently 35.48%.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Five stocks we like better than GSK
- How to Use the MarketBeat Stock Screener
- MarketBeat Week in Review – 11/13 – 11/17
- How to Invest in Casino Stocks
- 3 large caps with red hot RSIs with upside
- Your Comprehensive Guide to Investing in Bank Stocks
- Johnson Controls International: Nothing but upside for investors
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.